...
首页> 外文期刊>Liver international : >Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases.
【24h】

Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases.

机译:预后因素和临床得分的评估,以预测结直肠癌肝转移切除术后的存活率。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Patient outcome after resection of colorectal liver metastases can be predicted by various prognostic factors. Aims: Development of a model for risk stratification based on analysis of prognostic factors. METHODS: Data of 201 patients were collected prospectively and included in a single-centre trial. A total of 20 factors were analysed as to their influence on recurrence-free and overall survival. Independent prognostic factors were entered into a model of a clinical risk score. RESULTS: Median recurrence-free survival reached 24 months for all patients; median overall survival was 50 months. Only a synchronous manifestation of primary colorectal carcinoma and liver metastases, the presence of four or more metastases and a carcino-embryonic antigen level of 200 ng/ml or more significantly influenced recurrence-free and overall survival in the multivariate analysis. The derived risk stratification grouped the patients according to the following criteria: low risk, zero prognostic factors (n=112); intermediate risk, one factor (n=74); high risk, two or more factors (n=15). The median recurrence-free survival for low, intermediate and high risk were 30.0, 23.0 and 11.0 months, respectively; the median overall survival was 94.0, 40.0 and 33.0 months. Compared with the low-risk group, patients with intermediate risk demonstrated an increased hazard ratio (HR) of 1.57-fold for recurrence (P=0.018) and 1.91-fold for mortality (P=0.007). For the high-risk group, the HR rose significantly to 3.26 for recurrence (P<0.0005) and to 3.10 for mortality (P=0.001). CONCLUSIONS: The presented clinical score may allow for patients with colorectal liver metastases to be stratified appropriately and for optimization of their subsequent therapeutic management.
机译:背景:结直肠癌肝转移切除术后的患者预后可以通过各种预后因素进行预测。目的:基于对预后因素的分析,开发风险分层模型。方法:前瞻性收集201例患者的数据,并将其纳入单中心试验。分析了总共20个因素对无复发生存率和总体生存率的影响。将独立的预后因素输入临床风险评分模型。结果:所有患者的中位无复发生存期均达到24个月。中位总生存期为50个月。在多变量分析中,只有原发性大肠癌和肝转移的同步表现,四个或更多转移的存在以及200 ng / ml或更高的癌胚抗原水平显着影响无复发和总生存期。衍生风险分层根据以下标准对患者进行分组:低风险,零预后因素(n = 112);中等风险,一个因素(n = 74);高风险,两个或多个因素(n = 15)。低,中和高风险的无复发生存中位数分别为30.0、23.0和11.0个月;中位总生存期为94.0、40.0和33.0个月。与低风险组相比,中度风险患者的复发风险比(HR)增加了1.57倍(P = 0.018),死亡率增加了1.91倍(P = 0.007)。对于高风险组,HR复发率显着上升至3.26(P <0.0005),死亡率上升至3.10(P = 0.001)。结论:提出的临床评分可以使结直肠肝转移患者得到适当分层,并优化其后续治疗管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号